

Independent Auditor's Report

May 8th, 2025

The Board of Directors
Sun Pharma Japan Ltd.

Kuno Yasunari CPA Firm
Certified Public Accountant

Auditor's opinion

I have audited the accompanying financial statements, which comprise the balance sheet, the statement of income, the statement of changes in net assets, and notes to the financial statements of Sun Pharma Japan Ltd. (the "Company") for the fiscal year from April 1, 2024 to March 31, 2025.

In my opinion, the accompanying financial statements has been prepared in all material respects, for the fiscal year ended March 31, 2025, in accordance with accounting principles generally accepted in Japan.

Basis of Opinion

I conducted my audit in accordance with auditing standards generally accepted in Japan. My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statement section of my report. I am independent of the Company in accordance with the ethical requirements that are relevant to my audit of the financial statements in Japan, and I have fulfilled my other ethical responsibilities in accordance with these requirements. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Responsibilities of Management and the Corporate Auditor for the Financial Statements

Management is responsible for the preparation of these financial statements in accordance with accounting principles generally accepted in Japan, and for design and operation of such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern and disclosing, as required by accounting principles generally accepted in Japan, matters related to going concern.

The Corporate Auditor is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

My objectives is to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Misstatements can arise from fraud or error and are

considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with auditing standards generally accepted in Japan, I exercise professional judgement and maintain professional skepticism throughout the audit.

I also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion.
- Obtain an understanding of internal control relevant to the audit as part of our risk assessment in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exist or related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events of condition may cause the Company to cease to continue as a going concern.
- Evaluate whether the financial statements are presented and the disclosures contained therein prepared in accordance with accounting principles generally accepted in Japan.

I communicate with the Corporate Auditor regarding, among matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

Conflicts of Interest

I have no interest in the Company which should be disclosed in accordance with the Certified Public Accountants Act.

Notes to the Readers of Independent Auditor's Report

This is an English translation of the Independent Auditor's Report as required by the Companies Act of Japan for the conveniences of the reader.

Income Statements

Sun Pharma Japan Ltd.

From April 1, 2024

To March 31, 2025

(JPY)

Product Sales		12,859,420,819
Cost of Sales		8,095,854,223
Gross Profit		4,763,566,596
Selling, General and Administrative Expenses		5,007,135,356
Operating Profit		△ 243,568,760
Non-Operating Income		
Interest Income	625,680	
Dividend Income	1,005,372,459	
Miscellaneous Income	1,004,472	1,007,002,611
Non-Operating Expenses		
Interest Expense	19,977,839	
Forex Gain/Loss	1,235,272	21,213,111
Ordinary Profit		742,220,740
Special Loss		
Loss on sales of shares of subsidiaries	471,335,000	471,335,000
Profit before Income Tax		270,885,740
Corporate tax		950,961
Net Income		269,934,779

Balance Sheet
Sun Pharma Japan Ltd.
As of March 31, 2025

(JPY)

Assets		Liabilities	
Current Assets	10,768,946,997	Current Liabilities	10,424,276,044
Cash and Deposits	90,767,303	Trade Payable	1,901,712,605
Trade Receivable	5,311,852,654	Accounts Payable Other	551,085,034
Inter-Company Receivable	719,832,373	Inter-Company Payable	5,305,830,392
Inventories	4,560,163,988	Accrued Expenses	246,188,794
Prepaid Expenses	86,105,679	Deposits received	19,353,085
Other current assets	225,000	Provision for Bonus	302,835,305
		Short term Lease Liability	37,778,311
		Shot term loan	2,032,474,768
		Other Current Liabilities	23,397,125
		Consumption tax payable	3,620,625
Non-Current Assets	1,859,552,007	Non-Current Liabilities	143,203,294
Property and Equipment	197,071,024	Asset Retirement Obligation	33,757,000
Buildings	9,102,255	Provision For Pension	40,693,207
Leasehold Improvement	79,746,831	Long term Lease liability	68,753,087
Machinery & Equipment	294,828,097		
Leased Assets	223,401,591	Total Liability	10,567,479,338
Accumulated Depreciation	△ 410,007,750		
Intangible Assets	1,571,289,841		
Software	68,949,111	Equity	
Trademark	1,502,340,730	Shareholders Equity	2,061,019,666
Investments and Other Assets	91,191,142	Share Capital	158,000,000
Security Deposits	91,191,142	Capital Surplus	6,532,019,108
		Retained Earnings	△ 4,628,999,442
		Total Equity	2,061,019,666
Total Assets	12,628,499,004	Total Liabilities and Equity	12,628,499,004

Statements of Shareholders' Equity
Sun Pharma Japan Ltd.
From April 1, 2024
To March 31, 2025

	Share Capital	Capital Reserve			Retained Earnings			Total Shareholders' Equity	Total Equity
		Capital Surplus	Other Capital Reserve	Total Capital Reserve	Legal Reserve	Retained Earnings brought forward	Total Retained Earnings		
Balance at March 31, 2023	158,000,000	-	6,532,019,108	6,532,019,108	-	△ 4,898,934,221	△ 4,898,934,221	1,791,084,887	1,791,084,887
Changes of items during the period									
Net Income (Loss)						269,934,779	269,934,779	269,934,779	269,934,779
Total changes of items during the period	0		0	0		269,934,779	269,934,779	269,934,779	269,934,779
Balance at March 31, 2024	158,000,000	-	6,532,019,108	6,532,019,108	-	△ 4,628,999,442	△ 4,628,999,442	2,061,019,666	2,061,019,666